Lyell Immunopharma, INC Form 4 insider transactions

Director Richard Klausner reports the acquisition of 158,000 shares of Lyell Immunopharma at an average price of $0.6009.

Lyell Immunopharma's CFO, Charles W. Newton, purchased 200,000 shares of common stock at an average price of $0.5581 on March 17, 2025.

Lyell Immunopharma's CEO, Lynn Seely, purchased 175,000 shares of common stock at a weighted average price of $0.6068 on March 14, 2025.

Chief Business Officer Matthew Lang reports acquisition of stock and options in Lyell Immunopharma.

Lyell Immunopharma's CEO, Lynn Seely, reports acquisition of common stock and options in the company.

Stephen J. Hill, Chief Operating Officer of Lyell Immunopharma, reports the acquisition of stock and option awards.

Charles W. Newton, CFO of Lyell Immunopharma, reports the acquisition of stock and option awards, including restricted stock units and performance-based options, as per a recent SEC Form 4 filing.

Chief Scientific Officer Gary K. Lee reports acquisition of stock and option awards in Lyell Immunopharma, Inc.

Director Sumant Ramachandra acquired 260,000 options of Lyell Immunopharma, Inc. at a price of $0.9603 on October 31, 2024.

Director Robert Nelsen reports acquisition of options and indirect ownership of common stock through ARCH Venture Funds.

Director Hans Bishop reports the acquisition of 130,000 stock options in Lyell Immunopharma, Inc.

Director Richard Klausner reports the acquisition of stock options and updates to beneficial ownership of Lyell Immunopharma shares.

Director William Rieflin acquired 130,000 stock options in Lyell Immunopharma, Inc. on June 14, 2024, according to a Form 4 filing with the SEC.

Director Elizabeth Nabel acquired options to purchase 130,000 shares of Lyell Immunopharma stock on June 14, 2024.

Director Otis Brawley acquired 130,000 stock options in Lyell Immunopharma, Inc. on June 14, 2024.

Director Cathy Friedman reports the acquisition of 130,000 stock options in Lyell Immunopharma, Inc.